💊 Arzneimittel A-Z 🧬 Targets 🛠 Werkzeuge 📚 Leitfäden
Alle Arzneimittel Arzneimittelklassen Therapeutische Bereiche Nebenwirkungen
Leitfäden Glossar Zeitleiste
Vergleiche Arzneimittelreisen Arzneimittel-Wirkstoffgruppen
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Strontium Ranelate

CHEMBL3707306 Phase 4 Zugelassen Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
513.5 g/mol
LogP
—
Phase
4

Strontium ranelate is a dual-action bone agent used for the treatment of osteoporosis, combining the actions of both inhibiting osteoclast-mediated bone resorption and stimulating osteoblast-mediated bone formation by interacting with the calcium-sensing receptor. By simultaneously reducing bone breakdown and promoting bone synthesis, it improves bone microarchitecture and reduces fracture risk at both vertebral and non-vertebral sites. It has been restricted in some markets due to cardiovascular and venous thromboembolic risks.

Molekularmasse

513,5000 g/mol

TPSA

216,00 Ų

Therapeutische Bereiche

Osteoporosis

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D-Struktur

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
N#Cc1c(N(CC(=O)[O-])CC(=O)[O-])sc(C(=O)[O-])c1CC(=O)[O-].[Sr+2].[Sr+2]

                

                

                
                

                    
InChI

                    
InChI=1S/C12H10N2O8S.2Sr/c13-2-6-5(1-7(15)16)10(12(21)22)23-11(6)14(3-8(17)18)4-9(19)20;;/h1,3-4H2,(H,15,16)(H,17,18)(H,19,20)(H,21,22);;/q;2*+2/p-4

                

                

                

                    
                    

                        
Molecular Formula

                        
C12H6N2O8SSr2

                    

                    
                    

                        
HBD / HBA

                        
- / 11

                    

                    
                    

                        
Rotierbare Bindungen

                        
4

                    

                    
                    
                    

                        
Schwere Atome

                        
25

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Häufig gestellte Fragen

                

                    
                    

                        
                        

                            
Strontium ranelate is a dual-action bone agent used for the treatment of osteoporosis, combining the actions of both inhibiting osteoclast-mediated bone resorption and stimulating osteoblast-mediated bone formation by interacting with the calcium-sensing receptor. By simultaneously reducing bone breakdown and promoting bone synthesis, it improves bone microarchitecture and reduces fracture risk at both vertebral and non-vertebral sites. It has been restricted in some markets due to cardiovascular and venous thromboembolic risks.

                        

                    

                    

                    

                    

                    

                    

                        
                        

                            
Yes, Strontium Ranelate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL3707306.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 6918182.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
Medizinischer Haftungsausschluss

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.